ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Improved NCI Relations With FDA Cited As Model For Government Accord, Lasagna Committee Says

April 20, 1990

Revised Price Equivalent to Lower Dose of Avastin

November 8, 2012

Clinton’s FY97 Budget Sees $12.4 Billion For NIH, $2.28B For NCI

March 22, 1996

‘Approval to Apply’ For Proton Facility Upgrade Denied

February 24, 1989

In Brief: John Young to Leave NCI for ELM; Yates Looking for Chief Of Outpatient Services At RPI

March 18, 1988

Almost Half of Faculty on IRBs Have Industry Ties, Study Finds

September 26, 2003